PZ0385
PFE-360
≥98% (HPLC)
别名:
1-Methyl-4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-1H-pyrrole-2-carbonitrile, PF-06685360, PFE360
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
room temp
SMILES字符串
CN1C(C#N)=CC(C2=CNC3=C2C(N4CCOCC4)=NC=N3)=C1
InChI key
IYQTYHISVSPMSU-UHFFFAOYSA-N
生化/生理作用
LRRK2 modulator
PFE-360 (PF-06685360) is a poten and elective inhibitor of LRRK2 kinase.
警示用语：
Danger
危险声明
危险分类
Self-react. C
储存分类代码
5.2 - Organic peroxides and self-reacting hazardous materials
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
Kenneth Thirstrup et al.
Scientific reports, 7(1), 10300-10300 (2017-09-02)
Genetic variation in the leucine-rich repeat kinase 2 (LRRK2) gene is associated with risk of familial and sporadic Parkinson's disease (PD). To support clinical development of LRRK2 inhibitors as disease-modifying treatment in PD biomarkers for kinase activity, target engagement and
Andrew B West
Experimental neurology, 298(Pt B), 236-245 (2017-08-03)
In the translation of discoveries from the laboratory to the clinic, the track record in developing disease-modifying therapies in neurodegenerative disease is poor. A carefully designed development pipeline built from discoveries in both pre-clinical models and patient populations is necessary
Michael Aagaard Andersen et al.
Toxicology, 395, 15-22 (2018-01-09)
Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is no existing therapeutic approach to delay or stop progression. Genetic, biochemical and pre-clinical studies have provided evidence that leucine-rich-repeat-kinase-2 (LRRK2) kinase is involved in the pathogenesis of PD
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持